FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801--Alzheon, Inc., a clinical-stage biopharmaceutical company developing investigational therapies and diagnostic assays for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the peer-reviewed publication of “Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes” in Drugs. Full text i
Alzheon Announces Peer-Reviewed Publication Showing Oral Valiltramiprosate/ALZ-801 Achieves Sustained Plasma Biomarker Reductions Linked to Better Cognitive, Functional, and Brain Atrophy Outcomes in APOE4 Carriers with Early Alzheimer’s Disease
